New Publication Highlights Opportunities To Improve Medical Reimbursement Landscape

Explore Key Findings from the Investor Catalyst Hub’s Network Survey

Receiving authorization from the U.S. Food and Drug Administration (FDA) and securing nominal reimbursement coverage are two critical milestones that novel medical technologies must meet to scale market adoption and attract follow-on investment—but the process can take several years.

With innovative solutions likely to emerge from several of its programs and small business awards, the Advanced Research Projects Agency for Health (ARPA-H) seeks to deliver best-in-class services to shorten timelines and support agency-funded technologies in securing reimbursement.

To aid this effort, we issued a network survey to solicit feedback from key stakeholders on the reimbursement landscape for novel medical devices and diagnostics. Our Medtech Reimbursement Network Survey Brief captures valuable insights from our network that underscore the complexity of the reimbursement ecosystem and how resource constraints—particularly among smaller companies—impact end-user adoption.

Despite their knowledge of the regulatory approval process, survey respondents struggle to identify different pathways that may result in a faster journey toward reimbursement. They are working to determine when during development they should have a defined reimbursement roadmap, what specific evidence must be generated to drive buyer adoption, and how to gain access to payors and providers to understand investment priorities.

As ARPA-H works to accelerate the transition of breakthrough technologies to market, opportunities to support innovators in achieving reimbursement will remain a priority. Survey responses could inform the development of ARPA-H services and partnerships to support performers, maximize the potential for agency-funded efforts to reach reimbursement milestones, and improve health outcomes.